Immunological Biomarkers in Postinfectious Irritable Bowel Syndrome

Journal of Travel Medicine

Volumn 22, Issue 4, 2015, Pages 242-250

  Pike, Brian L ^a   Paden, Katie Ann ^a   Alcala, Ashley N ^a   Jaep, Kayla M ^a   Gormley, Robert P ^a   Maue, Alexander C ^a   Christmann, Benjamin S ^b   Elson, Charles O ^b   Riddle, Mark S ^a   Porter, Chad K ^a  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; BACTERIUM ANTIBODY; INTERLEUKIN DERIVATIVE;

ADULT; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CYTOKINE RESPONSE; HUMAN; IDIOPATHIC DISEASE; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; POSTINFECTIOUS IRRITABLE BOWEL SYNDROME; SEROLOGY; BLOOD; CAMPYLOBACTER; CAMPYLOBACTERIOSIS; COMPLICATION; FEMALE; GASTROENTERITIS; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; IRRITABLE BOWEL SYNDROME; MICROBIOLOGY; PROCEDURES; SALMONELLA; SALMONELLOSIS; SHIGELLA; SHIGELLOSIS; SOLDIER; STATISTICS; UNITED STATES;

ADULT; ANTIBODIES, BACTERIAL; BIOMARKERS; CAMPYLOBACTER; CAMPYLOBACTER INFECTIONS; CHEMOKINE CCL4; DYSENTERY, BACILLARY; FEMALE; GASTROENTERITIS; HUMANS; INTERLEUKINS; IRRITABLE BOWEL SYNDROME; MALE; MILITARY PERSONNEL; MONITORING, IMMUNOLOGIC; SALMONELLA; SALMONELLA INFECTIONS; SHIGELLA; STATISTICS AS TOPIC; UNITED STATES;

EID: 84934805769     PISSN: 11951982     EISSN: 17088305     Source Type: Journal    
DOI: 10.1111/jtm.12218     Document Type: Article

References (63)

1. Furman DL, Cash BD,. The role of diagnostic testing in irritable bowel syndrome. Gastroenterol Clin North Am 2011; 40: 105-119.
2. Talley NJ,. Functional gastrointestinal disorders as a public health problem. Neurogastroenterol Motil 2008; 20 (Suppl 1): 121-129.
3. DiBonaventura M, Sun SX, Bolge SC, et al., Health-related quality of life, work productivity and health care resource use associated with constipation predominant irritable bowel syndrome. Curr Med Res Opin 2011; 27: 2213-2222.
4. Lembo AJ, Neri B, Tolley J, et al., Use of serum biomarkers in a diagnostic test for irritable bowel syndrome. Aliment Pharmacol Ther 2009; 29: 834-842.
5. Pimentel M, Talley NJ, Quigley EM, et al., Report from the multinational irritable bowel syndrome initiative 2012. Gastroenterology 2013; 144: e1-e5.
6. Goo YA, Cain K, Jarrett M, et al., Urinary proteome analysis of irritable bowel syndrome (IBS) symptom subgroups. J Proteome Res 2012; 11: 5650-5662.
7. Ohman L, Stridsberg M, Isaksson S, et al., Altered levels of fecal chromogranins and secretogranins in IBS: relevance for pathophysiology and symptoms? Am J Gastroenterol 2012; 107: 440-447.
8. Sidhu R, McAlindon ME, Leeds JS, et al., The role of serum chromogranin a in diarrhoea predominant irritable bowel syndrome. J Gastrointestin Liver Dis 2009; 18: 23-26.
9. Ahmed I, Greenwood R, Costello Bde L, et al., An investigation of fecal volatile organic metabolites in irritable bowel syndrome. PLoS One 2013; 8: e58204.
10. El-Salhy M, Gundersen D, Hatlebakk JG, et al., Abnormal rectal endocrine cells in patients with irritable bowel syndrome. Regul Pept 2014; 188: 60-65.
11. El-Salhy M, Gundersen D, Hatlebakk JG, Hausken T,. Chromogranin a cell density as a diagnostic marker for lymphocytic colitis. Dig Dis Sci 2012; 57: 3154-3159.
12. Kim HS, Lim JH, Park H, Lee SI,. Increased immunoendocrine cells in intestinal mucosa of postinfectious irritable bowel syndrome patients 3 years after acute shigella infection-an observation in a small case control study. Yonsei Med J 2010; 51: 45-51.
13. Kindt S, Van Oudenhove L, Broekaert D, et al., Immune dysfunction in patients with functional gastrointestinal disorders. Neurogastroenterol Motil 2009; 21: 389-398.
14. Lee KJ, Kim YB, Kim JH, et al., The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol 2008; 23: 1689-1694.
15. Spiller RC, Jenkins D, Thornley JP, et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804-811.
16. Walker MM, Talley NJ, Prabhakar M, et al., Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 2009; 29: 765-773.
17. Aerssens J, Camilleri M, Talloen W, et al., Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008; 6: 194-205.
18. Belmonte L, Beutheu Youmba S, Bertiaux-Vandaele N, et al., Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype. PLoS One 2012; 7: e42777.
19. Piche T, Barbara G, Aubert P, et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators. Gut 2009; 58: 196-201.
20. Shiotani A, Kusunoki H, Kimura Y, et al., S100a expression and interleukin-10 polymorphisms are associated with ulcerative colitis and diarrhea predominant irritable bowel syndrome. Dig Dis Sci 2013; 58: 2314-2323.
21. Yu YB, Zuo XL, Zhao QJ, et al., Brain-derived neurotrophic factor contributes to abdominal pain in irritable bowel syndrome. Gut 2012; 61: 685-694.
22. Chang L, Adeyemo M, Karagiannides I, et al., Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol 2012; 107: 262-272.
23. Clarke G, Fitzgerald P, Cryan JF, et al., Tryptophan degradation in irritable bowel syndrome: evidence of indoleamine 2,3-dioxygenase activation in a male cohort. BMC Gastroenterol 2009; 9: 6.
24. Clarke G, Fitzgerald P, Hennessy AA, et al., Marked elevations in pro-inflammatory polyunsaturated fatty acid metabolites in females with irritable bowel syndrome. J Lipid Res 2010; 51: 1186-1192.
25. Dinan TG, Clarke G, Quigley EM, et al., Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors. Am J Gastroenterol 2008; 103: 2570-2576.
26. Dinan TG, Quigley EM, Ahmed SM, et al., Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006; 130: 304-311.
27. Ohman L, Lindmark AC, Isaksson S, et al., Increased TLR2 expression on blood monocytes in irritable bowel syndrome patients. Eur J Gastroenterol Hepatol 2012; 24: 398-405.
28. Rana SV, Sharma S, Sinha SK, et al., Pro-inflammatory and anti-inflammatory cytokine response in diarrhoea-predominant irritable bowel syndrome patients. Trop Gastroenterol 2012; 33: 251-256.
29. Scully P, McKernan DP, Keohane J, et al., Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am J Gastroenterol 2010; 105: 2235-2243.
30. Semnani S, Roshandel G, Keshtkar A, et al., Serum leptin levels and irritable bowel syndrome: a new hypothesis. J Clin Gastroenterol 2009; 43: 826-830.
31. Clarke G, McKernan DP, Gaszner G, et al., A distinct profile of tryptophan metabolism along the kynurenine pathway downstream of toll-like receptor activation in irritable bowel syndrome. Front Pharmacol 2012; 3: 90.
32. Del Valle-Pinero AY, Martino AC, Taylor TJ, et al., Pro-inflammatory chemokine c-c motif ligand 16 (ccl-16) dysregulation in irritable bowel syndrome (IBS): a pilot study. Neurogastroenterol Motil 2011; 23: 1092-1097.
33. Hod K, Dickman R, Sperber A, et al., Assessment of high-sensitivity CRP as a marker of micro-inflammation in irritable bowel syndrome. Neurogastroenterol Motil 2011; 23: 1105-1110.
34. Schmulson M, Pulido-London D, Rodriguez O, et al., Lower serum IL-10 is an independent predictor of IBS among volunteers in Mexico. Am J Gastroenterol 2012; 107: 747-753.
35. Halvorson HA, Schlett CD, Riddle MS,. Postinfectious irritable bowel syndrome-a meta-analysis. Am J Gastroenterol 2006; 101: 1894-1899.
36. Shah ED, Riddle MS, Chang C, Pimentel M,. Estimating the contribution of acute gastroenteritis to the overall prevalence of irritable bowel syndrome. J Neurogastroenterol Motil 2012; 18: 200-204.
37. Dai C, Jiang M,. The incidence and risk factors of post-infectious irritable bowel syndrome: a meta-analysis. Hepatogastroenterology 2012; 59: 67-72.
38. Collins SM, Denou E, Verdu EF, Bercik P,. The putative role of the intestinal microbiota in the irritable bowel syndrome. Dig Liver Dis 2009; 41: 850-853.
39. Rutella S, Locatelli F,. Intestinal dendritic cells in the pathogenesis of inflammatory bowel disease. World J Gastroenterol 2011; 17: 3761-3775.
40. Wells JM, Rossi O, Meijerink M, van Baarlen P,. Epithelial crosstalk at the microbiota-mucosal interface. Proc Natl Acad Sci U S A 2011; 108 (Suppl 1): 4607-4614.
41. Fukudo S, Kanazawa M,. Gene, environment, and brain-gut interactions in irritable bowel syndrome. J Gastroenterol Hepatol 2011; 26 (Suppl 3): 110-115.
42. Mearin F, Perello A, Balboa A, et al., Pathogenic mechanisms of postinfectious functional gastrointestinal disorders: results 3 years after gastroenteritis. Scand J Gastroenterol 2009; 44: 1173-1185.
43. Jung IS, Kim HS, Park H, Lee SL,. The clinical course of post-infectious irritable bowel syndrome: a five-year follow-up study. J Clin Gastroenterol 2009; 43: 7.
44. Jung IS, Kim HS, Park H, Lee SI,. The clinical course of postinfectious irritable bowel syndrome: a five-year follow-up study. J Clin Gastroenterol 2009; 43: 534-540.
45. Moore M, Eiseman E, Fisher G, et al., Harnessing full value from the dod serum repository and the defense medical surveillance system. Santa Monica, CA: RAND Corporation, 2010. Available at: http://www.rand.org/pubs/monographs/MG875.
46. Rubertone MV, Brundage JF,. The defense medical surveillance system and the department of defense serum repository: glimpses of the future of public health surveillance. Am J Public Health 2002; 92: 1900-1904.
47. Darkoh C, Comer L, Zewdie G, et al., Chemotactic chemokines are important in the pathogenesis of irritable bowel syndrome. PLoS One 2014; 9: e93144.
48. Liebregts T, Adam B, Bredack C, et al., Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132: 913-920.
49. McKernan DP, Gaszner G, Quigley EM, et al., Altered peripheral toll-like receptor responses in the irritable bowel syndrome. Aliment Pharmacol Ther 2011; 33: 1045-1052.
50. Hand TW, Dos Santos LM, Bouladoux N, et al., Acute gastrointestinal infection induces long-lived microbiota-specific T cell responses. Science 2012; 337: 1553-1556.
51. Salonen A, de Vos WM, Palva A,. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology 2010; 156 (Pt 11): 3205-3215.
52. Tosh PK, McDonald LC,. Infection control in the multidrug-resistant era: tending the human microbiome. Clin Infect Dis 2012; 54: 707-713.
53. Rajilic-Stojanovic M, Biagi E, Heilig HG, et al., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011; 141: 1792-1801.
54. Talley NJ, Fodor AA,. Bugs, stool, and the irritable bowel syndrome: too much is as bad as too little? Gastroenterology 2011; 141: 1555-1559.
55. Pimentel M, Lembo A, Chey WD, et al., Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32.
56. Sisson G, Ayis S, Sherwood RA, Bjarnason I,. Randomised clinical trial: a liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome-a 12 week double-blind study. Aliment Pharmacol Ther 2014; 40: 51-62.
57. Konkel ME, Samuelson DR, Eucker TP, et al., Invasion of epithelial cells by campylobacter jejuni is independent of caveolae. Cell Commun Signal 2013; 11: 100.
58. Pimentel M, Chang C, Lembo A, et al., Anti-vinculin antibodies: multicenter validation of a diagnostic blood test for irritable bowel syndrome. American College of Gastroenterology 78th Annual Scientific Meeting. San Diego, CA, 2013.
59. Schoepfer AM, Schaffer T, Seibold-Schmid B, et al., Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients. Neurogastroenterol Motil 2008; 20: 1110-1118.
60. Card TR, Siffledeen J, West J, Fleming KM,. An excess of prior irritable bowel syndrome diagnoses or treatments in celiac disease: evidence of diagnostic delay. Scand J Gastroenterol 2013; 48: 801-807.
61. Havelaar AH, Ivarsson S, Lofdahl M, Nauta MJ,. Estimating the true incidence of campylobacteriosis and salmonellosis in the European Union, 2009. Epidemiol Infect 2013; 141: 293-302.
62. MacDougall L, Majowicz S, Dore K, et al., Under-reporting of infectious gastrointestinal illness in British Columbia, Canada: who is counted in provincial communicable disease statistics? Epidemiol Infect 2008; 136: 248-256.
63. Thomas MK, Majowicz SE, Sockett PN, et al., Estimated numbers of community cases of illness due to salmonella, campylobacter and verotoxigenic Escherichia coli: pathogen-specific community rates. Can J Infect Dis Med Microbiol 2006; 17: 229-234.